Article Text
PDF
Statistics from Altmetric.com
Central to Watts and Newson’s argument in their seminal paper ‘Is there a duty to routinely reinterpret genomic variant classifications?’ is that diagnostic laboratories are not morally obligated to actively reinterpret variants of uncertain significance (VUS) due to the superior outcomes offered by next-generation sequencing (NGS) compared with traditional methods.1 NGS technologies can identify, analyse and interpret millions of genetic variations at once. For example, ‘the use of conventional molecular assays in clinical contexts could require doing a lot of assays for various mutations. Using these different assays, more tissue may be required. These targets can accurately be questioned using NGS technology in a single test.’2 If NGS-based genomic sequencing is reliable and its output outweighs the potential harm of uncertainties, then, it is plausible to say that those test providers cannot incur a moral duty to actively reinterpret VUS because there won’t be any need to do so.1
Despite its seeming reliability, diagnostic laboratories face enormous challenges in implementing NGS-based …
Footnotes
Twitter @DrVic_Exotic
Contributors I am the sole author of this article.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.
Linked Articles
Read the full text or download the PDF:
Other content recommended for you
- Is there a duty to routinely reinterpret genomic variant classifications?
- Optimising clinical care through CDH1-specific germline variant curation: improvement of clinical assertions and updated curation guidelines
- The UCL low-density lipoprotein receptor gene variant database: pathogenicity update
- Reclassification of BRCA1 and BRCA2 variants of uncertain significance: a multifactorial analysis of multicentre prospective cohort
- Variant reclassification and clinical implications
- Clinical implications of VUS reclassification in a single-centre series from application of ACMG/AMP classification rules specified for BRCA1/2
- Modern genomic techniques in the identification of genetic causes of cardiomyopathy
- Retesting of women who are negative for a BRCA1 and BRCA2 mutation using a 20-gene panel
- International initiative for a curated SDHB variant database improving the diagnosis of hereditary paraganglioma and pheochromocytoma
- Genomics for paediatricians: promises and pitfalls